Roche’s Second-Quarter Sales Held Back by Blockbuster Eye Drug

Roche Holding’s results showed a slower-than-expected recovery for eye blockbuster Vabysmo as investors look to a key new drug to power growth ahead.

By Fabienne Kinzelmann · Bloomberg Markets

Roche Holding’s results showed a slower-than-expected recovery for eye blockbuster Vabysmo as investors look to a key new drug to power growth ahead.